The Food and Drug Administration has quietly dropped its enforcement action against Whoop, the maker of a screenless fitness wearable worn by more than 1 million people, ending a year-long standoff over whether the company’s Blood Pressure Insights feature amounts to an unapproved medical device. The agency notified Whoop of its decision in June 2026, according to reporting by STAT News, closing a dispute that began when the FDA sent the company a formal warning letter in July 2025.
What the Feature Actually Does
Blood Pressure Insights, introduced as part of the premium Whoop MG hardware, uses optical sensors on the wrist-worn band to generate an estimated blood pressure reading during sleep, without a traditional inflatable cuff. Whoop has marketed the feature as a way for everyday users to track trends in their cardiovascular health alongside metrics like heart rate variability, recovery scores and sleep staging that the company is known for among athletes and fitness enthusiasts.
Why the FDA Objected
In its July 2025 warning letter, the FDA argued that any device offering a measurement or estimation of blood pressure is inherently tied to diagnosing hypotension and hypertension, conditions that fall squarely within the definition of a regulated medical device. That determination meant Whoop would have needed to pursue formal clearance, similar to the pathway other companies, including Whoop’s rival Withings, have used for blood-pressure-adjacent features. The agency’s letter put Whoop in the position of either seeking clearance, pulling the feature, or contesting the classification.
Whoop’s Pushback
Whoop chief executive Will Ahmed pushed back publicly, framing the feature as wellness information rather than a diagnostic tool, and arguing that consumers have a right to access data about their own bodies without regulators dictating the terms. Rather than removing Blood Pressure Insights, Whoop kept the feature live throughout the dispute while adjusting how the data was presented to users, according to STAT’s reporting and coverage in the Boston Globe. That approach amounted to a bet that the agency’s own guidance was shifting under it. Ahmed’s public statements framed the dispute as part of a larger pattern of federal regulators struggling to categorize a new generation of consumer devices that blur the line between casual wellness tracking and clinically meaningful measurement, an argument that resonated with a customer base of athletes and health-conscious professionals who have made Whoop, alongside Oura and Apple Watch, one of the most visible wearables in the fitness and recovery market.
A Shifting Regulatory Line
The turning point came in early January 2026, when the FDA issued new draft guidance clarifying that optical blood-pressure-style sensing could remain in the lower-risk wellness category, so long as companies avoid describing the output as medical-grade or diagnostic. That guidance gave Whoop room to keep offering the feature as a recovery and activity biomarker rather than a clinical blood pressure monitor, and appears to have been the basis for the FDA closing its case in June 2026 after Whoop made adjustments to the feature’s framing.
Caveats and Unresolved Questions
The resolution has not settled the underlying debate. Public health researchers and regulatory experts who have examined the case, including analysis published in the Journal of Medical Internet Research, warn that the FDA’s updated wellness-category guidance is still ambiguous and could allow consumer devices to imply clinical accuracy without the validation studies that a cleared medical device requires. Critics note that optical blood pressure estimation from the wrist has historically been less accurate than cuff-based measurement, particularly across different skin tones and body types, and that consumers may not understand the distinction between a wellness estimate and a diagnostic reading.
What Comes Next
The episode is likely to serve as a template for how the FDA handles a wave of similar wearable features from competitors racing to add more clinical-sounding metrics, from Oura’s glucose and metabolic tracking to Samsung’s new AI health assistant. Whoop has signaled it plans to keep expanding sensor-based insights on its devices, and the outcome suggests that going forward, wearable makers may be able to ship blood-pressure-adjacent features as wellness tools as long as they avoid explicit diagnostic marketing language, a distinction that regulators, plaintiffs’ lawyers and consumers alike are still working out in practice. For now, the practical lesson for the wearable industry is that persistence and public pressure, combined with a willingness to tweak how a feature is described rather than pulling it outright, can be an effective strategy against FDA enforcement, even as the agency continues to write the rules for this category in real time rather than in advance of new product launches.
